Last updated on October 2018

Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

Brief description of study

The rationale of this study is to further fine-tune and individualize prophylactic treatment of patients with severe Haemophilia A with the goal of keeping the trough FVIII level above 1% between doses. Because trough FVIII levels are likely to be important predictors of the efficacy of prophylaxis, the focus of this study is on PK data.

Clinical Study Identifier: NCT02256917

Contact Investigators or Research Sites near you

Start Over

Cristina Solomon, MD

Nara Medical University Hospital
Kashihara, Japan